Vitrolife's EmbryoGlue medium increases implantation and pregnancy rates

In a study presented at the on-going ESHRE conference in Istanbul, Vitrolife's (STO:VITR) patent protected medium EmbryoGlue® has once again been proven to increase both implantation and pregnancy rates, regardless of hormone stimulation of the endometrium or not.

Dr. Nakagawa from Japan, who performed the study, investigated whether the preparation method of the endometrium, the lining of the uterus, before transfer had an effect on pregnancy rate or not. The prospective randomized study included 203 patients under the age of 40, all with four or more previous implantation failures. 101 of the women had embryo transfer in a natural ovulation cycle, and 102 women were prepared by hormone replacement cycle. Patients in each group were allocated to transfer with either EmbryoGlue® or a transfer medium with no hyaluronan.

The study showed that the pregnancy rate increased significantly for the group receiving transfer in EmbryoGlue®. In the group with natural cycles it increased from 10% till 31.4% and in the group receiving transfer in a hormone stimulated cycle from 15.7% to 41.2%

"I am very happy to present these data, showing that women with many previous implantation failures have a chance of becoming parents," says Dr. Nakagawa.

EmbryoGlue® is a medium patent protected by Vitrolife, enriched with hyaluronan, a natural substance abundant in all tissues in the body. It has a unique combination of a high concentration of hyaluronan and recombinant albumin. EmbryoGlue® is used when transferring embryos into the woman as the final step of an IVF treatment.

The use of EmbryoGlue® for embryo transfer has been analysed in numerous studies, showing an increased treatment success independent of patient age, day of transfer and now also preparation of the endometrium.

Source: Vitrolife


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Is COVID-19 more severe in pregnancy?